-$0.13 EPS Expected for IMV Inc. (NASDAQ:IMV) This Quarter


Share on StockTwits

Wall Street brokerages expect IMV Inc. (NASDAQ:IMV) to report ($0.13) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for IMV’s earnings, with estimates ranging from ($0.14) to ($0.11). IMV reported earnings per share of ($0.14) during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The company is scheduled to report its next quarterly earnings report on Friday, May 21st.

According to Zacks, analysts expect that IMV will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.38). For the next year, analysts anticipate that the business will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.82) to ($0.39). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow IMV.

IMV (NASDAQ:IMV) last issued its quarterly earnings data on Tuesday, March 16th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. IMV had a negative net margin of 9,661.54% and a negative return on equity of 180.04%.

A number of equities analysts have commented on IMV shares. National Bankshares dropped their price objective on shares of IMV from $7.00 to $5.25 and set a “sector perform” rating for the company in a research note on Thursday, March 18th. Leede Jones Gab reaffirmed a “speculative buy” rating on shares of IMV in a research note on Thursday, March 18th. Raymond James reaffirmed a “market perform” rating and set a $3.00 price target on shares of IMV in a research note on Thursday, March 18th. Finally, Zacks Investment Research cut shares of IMV from a “hold” rating to a “sell” rating in a research note on Thursday, February 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.93.

Shares of NASDAQ:IMV traded down $0.08 on Monday, reaching $2.69. The company’s stock had a trading volume of 4,383 shares, compared to its average volume of 268,703. IMV has a 52-week low of $1.53 and a 52-week high of $6.82. The company has a market cap of $181.92 million, a P/E ratio of -5.85 and a beta of 1.69. The company has a 50-day simple moving average of $3.21 and a 200 day simple moving average of $3.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.03 and a current ratio of 7.03.

Large investors have recently bought and sold shares of the company. Toronto Dominion Bank raised its stake in shares of IMV by 1,747.5% during the 4th quarter. Toronto Dominion Bank now owns 10,069 shares of the company’s stock worth $31,000 after acquiring an additional 9,524 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of IMV during the 3rd quarter worth approximately $73,000. Hartford Financial Management Inc. raised its stake in shares of IMV by 17.9% during the 4th quarter. Hartford Financial Management Inc. now owns 45,315 shares of the company’s stock worth $140,000 after acquiring an additional 6,875 shares in the last quarter. Scotia Capital Inc. raised its stake in shares of IMV by 23.6% during the 4th quarter. Scotia Capital Inc. now owns 47,884 shares of the company’s stock worth $147,000 after acquiring an additional 9,145 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of IMV by 4,036.2% during the 3rd quarter. Morgan Stanley now owns 40,824 shares of the company’s stock worth $182,000 after acquiring an additional 39,837 shares in the last quarter. Institutional investors and hedge funds own 20.74% of the company’s stock.

IMV Company Profile

IMV Inc operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities.

Featured Article: Capital Gains

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IMV (NASDAQ:IMV)

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.